W
Walter L. Eaton
Researcher at Dartmouth College
Publications - 17
Citations - 3235
Walter L. Eaton is an academic researcher from Dartmouth College. The author has contributed to research in topics: Radiation therapy & Small-cell carcinoma. The author has an hindex of 13, co-authored 17 publications receiving 3177 citations. Previous affiliations of Walter L. Eaton include Dartmouth–Hitchcock Medical Center.
Papers
More filters
Journal ArticleDOI
A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer.
Robert O. Dillman,Stephen L. Seagren,Kathleen J. Propert,Julio Guerra,Walter L. Eaton,Michael C. Perry,Robert W. Carey,Emil Frei,Mark R. Green +8 more
TL;DR: In patients with Stage III non-small-cell lung cancer, induction chemotherapy with cisplatin and vinblastine before radiation significantly improves median survival and doubles the number of long-term survivors, as compared with radiation therapy alone.
Journal ArticleDOI
Improved Survival in Stage III Non-Small-Cell Lung Cancer: Seven-Year Follow-up of Cancer and Leukemia Group B (CALGB) 8433 Trial
TL;DR: Long-term follow-up confirms that patients with stage III NSCLC who receive 5 weeks of chemotherapy with cisplatin and vinblastine before radiation therapy have a 4.1-month increase in median survival.
Journal ArticleDOI
Chemotherapy with or without Radiation Therapy in Limited Small-Cell Carcinoma of the Lung
Michael C. Perry,Walter L. Eaton,Kathleen J. Propert,J H Ware,B Zimmer,A P Chahinian,A Skarin,Robert W. Carey,Harvey Kreisman,C Faulkner +9 more
TL;DR: The addition of radiotherapy of the primary tumor to combination chemotherapy improved both complete-response rates and survival, with increased but acceptable toxicity.
Journal ArticleDOI
Prognostic factors in small-cell carcinoma of the lung: an analysis of 1,521 patients.
Donna Spiegelman,L H Maurer,J H Ware,Michael C. Perry,A P Chahinian,Robert L. Comis,Walter L. Eaton,B Zimmer,Mark R. Green +8 more
TL;DR: Changing character of the study population limits the ability to determine retrospectively how much improvements in therapy contributed to the positive changes in failure-free survival, overall survival, and long-term survival observed in the sequentially studied population.
Journal ArticleDOI
Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study.
L H Maurer,James E. Herndon,Donna Hollis,Joseph Aisner,Robert W. Carey,Arthur T. Skarin,Michael C. Perry,Walter L. Eaton,L L Zacharski,S Hammond,Mark R. Green +10 more
TL;DR: Warfarin does not appear to improve outcome significantly in limited-stage SCLC, however, the differences in some variables between populations before the protocol amendment correspond to the favorable effects of anticoagulants observed in previous studies.